The Scandinavian Solutions for Wellness study - a two-arm observational study on the effectiveness of lifestyle intervention on subjective well-being and weight among persons with psychiatric disorders

BMC Psychiatry

Volumn 10, Issue , 2010, Pages

  Porsdal, Vibeke ^a   Beal, Catherine ^b   Kleivenes, Ole K ^c   Martinsen, Egil W ^d   Lindström, Eva ^e   Nilsson, Harriet ^f   Svanborg, Pär ^g  

^a Eli Lilly A/S   (Denmark)

^b Keyrus Biopharma   (France)

^c Eli Lilly Norge AS   (Norway)

^d AKER UNIVERSITY HOSPITAL   (Norway)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f ICON Clinical Research   (Sweden)

^g KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT DISORDER; CONTROLLED STUDY; DEPRESSION; EDUCATION PROGRAM; EXERCISE; FEMALE; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NUTRITION EDUCATION; OBSERVATIONAL STUDY; SCANDINAVIA; SCHIZOPHRENIA; THERAPY EFFECT; TREATMENT RESPONSE; WAIST CIRCUMFERENCE; WEIGHT GAIN; WEIGHT REDUCTION; WELLBEING; BODY WEIGHT; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; HEALTH CARE QUALITY; HEALTH EDUCATION; HEALTH STATUS; INFORMATION PROCESSING; LIFESTYLE; METHODOLOGY; MULTICENTER STUDY; OBESITY; ORGANIZATION AND MANAGEMENT; OUTCOME ASSESSMENT; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE;

ADULT; ANTIPSYCHOTIC AGENTS; BODY WEIGHT; DATA COLLECTION; FEMALE; HEALTH EDUCATION; HEALTH STATUS; HUMANS; LIFE STYLE; MALE; MENTAL DISORDERS; OBESITY; OUTCOME ASSESSMENT (HEALTH CARE); PROGRAM EVALUATION; QUESTIONNAIRES; SCANDINAVIA; SCHIZOPHRENIA; WAIST CIRCUMFERENCE; WEIGHT GAIN; WEIGHT LOSS;

EID: 77953262656     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-10-42     Document Type: Article

References (35)

1. World Health Organ Tech Rep Ser Obesity: preventing and managing the global epidemic. Report of a WHO consultation 2000, 894:i-xii. 1-253, World Health Organ Tech Rep Ser.
2. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, Degraba TJ, Gorelick PB, Guyton JR, Hart RG, Howard G, Kelly-Hayes M, Nixon JV, Sacco RL. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 2006, 37:1583-633.
3. Kawachi I. Physical and psychological consequences of weight gain. J Clin Psychiatry 1999, 60:5-9.
4. Holt RIG, Peveler RC. Obesity, serious mental illness and antipsychotic drugs. Diabetes Obes Metab 2009, 11:665-79. 10.1111/j.1463-1326.2009.01038.x, 19476478.
5. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents. JAMA 2009, 302:1765-1773. 10.1001/jama.2009.1549, 19861668.
6. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003, 28:83-96. 10.1016/S0306-4530(02)00114-2, 12504074.
7. Garland EJ, Remick RA, Zis AP. Weight gain with antidepressants and lithium. J Clin Psychopharmacol 1988, 8:323-30. 10.1097/00004714-198810000-00003, 3053797.
8. Pijl H, Meinders AE. Bodyweight change as an adverse effect of drug treatment. Mechanisms and management. Drug Saf 1996, 14:329-42. 10.2165/00002018-199614050-00005, 8800628.
9. Chen CK, Chen YC, Huang YS. Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up. Psychiatry Clin Neurosci 2009, 63:17-22. 10.1111/j.1440-1819.2008.01886.x, 19067997.
10. Kwon JS, Choi JS, Bahk WM, Yoon Kim C, Hyung Kim C, Chul Shin Y, Park BJ, Geun Oh C. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial. J Clin Psychiatry 2006, 67:547-553. 10.4088/JCP.v67n0405, 16669719.
11. Pendlebury J, Bushe CJ, Wildgust HJ, Holt RI. Long-term maintenance of weight loss in patients with severe mental illness through a behavioural treatment programme in the UK. Acta Psychiatr Scand 2007, 115:286-94. 10.1111/j.1600-0447.2006.00906.x, 17355519.
12. Lee SJ, Choi EJ, Kwon JS. A naturalistic multicenter trial of a 12-week weight management program for overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2008, 69:555-62. 10.4088/JCP.v69n0406, 18312061.
13. Vreeland B, Minsky S, Menza M, Rigassio Radler D, Roemheld-Hamm B, Stern R. A program for managing weight gain associated with atypical antipsychotics. Psychiatr Serv 2003, 54:1155-7. 10.1176/appi.ps.54.8.1155, 12883145.
14. Hoffmann VP, Ahl J, Meyers A, Schuh L, Shults KS, Collins DM, Jensen L. Wellness intervention for patients with serious and persistent mental illness. J Clin Psychiatry 2005, 66:1576-79. 10.4088/JCP.v66n1213, 16401160.
15. Bushe CJ, McNamara D, Haley C, McCrossan MF, Devitt P. Weight management in a cohort of Irish inpatients with serious mental illness (SMI) using a modular behavioural programme. A preliminary service evaluation. BMC Psychiatry 2008, 8:76. 10.1186/1471-244X-8-76, 2551599, 18793390.
16. Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry 2004, 65:471-7. 10.4088/JCP.v65n0404, 15119908.
17. Poulin MJ, Chaput JP, Simard V, Vincent P, Bernier J, Gauthier Y, Lanctôt G, Saindon J, Vincent A, Gagnon S, Tremblay A. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme. Aust N Z J Psychiatry 2007, 41:980-9. 10.1080/00048670701689428, 17999270.
18. Evans S, Newton R, Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. Aust N Z J Psychiatry 2005, 39:479-86.
19. Alvarez-Jiménez M, González-Blanch C, Vázquez-Barquero JL, Pérez-Iglesias R, Martínez-García O, Pérez-Pardal T, Ramírez-Bonilla ML, Crespo-Facorro B. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: A randomized controlled trial. J Clin Psychiatry 2006, 67:1253-60. 10.4088/JCP.v67n0812, 16965204.
20. Khazaal Y, Fresard E, Rabia S, Chatton A, Rothen S, Pomini V, Grasset F, Borgeat F, Zullino D. Cognitive behavioural therapy for weight gain associated with antipsychotic drugs. Schizophr Res 2007, 91:169-77. 10.1016/j.schres.2006.12.025, 17306507.
21. Littrell KH, Hilligoss NM, Kirshner CD, Petty RG, Johnson CG. The effects of an educational intervention on antipsychotic-induced weight gain. J Nur Scholarsh 2003, 35:237-41.
22. Brar JS, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R. Effects of ehavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2005, 66:205-12. 10.4088/JCP.v66n0208, 15705006.
23. Smith S, Yeomans D, Bushe CJ, Eriksson C, Harrison T, Holmes R, Mynors-Wallis L, Oatway H, Sullivan G. A well-being programme in severe mental illness. Reducing risk for physical ill-health: A post-programme service evaluation at 2 years. Eur Psychiatry 2007, 22:413-8. 10.1016/j.eurpsy.2007.07.002, 17765483.
24. Mauri M, Simoncini M, Castrogiovanni S, Iovieno N, Cecconi D, Dell'Agnello G, Quadrigli M, Rossi A, Donda P, Fagiolini A, Cassano GB. A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine. Pharmacotherapy 2008, 41:17-23.
25. Gabriele JM, Dubbert PM, Reeves RR. Efficacy of behavioural interventions in managing atypical antipsychotic weight gain. Obesity 2009, 10:442-455.
26. Ganguli R. Behavioral Therapy for Weight Loss in Patients With Schizophrenia. J Clin Psychiatry 2007, 68:19-25. 10.4088/JCP.0607e14, 17539696.
27. Alvarez-Jiménez M, Hetrick SE, González-Blanch C, Gleeson JF, McGorry PD. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 2008, 193:101-107. 10.1192/bjp.bp.107.042853, 18669990.
28. Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database of Systematic Reviews. 2007, 24:CD005148.
29. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995, 10:133-138.
30. Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, Andresen B. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001, 50:79-88. 10.1016/S0920-9964(00)00166-3, 11378316.
31. Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann Med 2001, 33:328-36. 10.3109/07853890109002086, 11491191.
32. Guy W. Clinical Global Impression (CGI). Handbook of psychiatric measures 2000, 100-102. American Psychiatric Association, Washington, DC, Rush AJ.
33. Naber D, Walther A, Kircher T, Hayek D, Holzbach R. Subjective effects of neuroleptics predict compliance. Prediction of neuroleptic treatment outcome in schizophrenia. Concepts and methods 1994, 85-98. Springer, Heidelberg, Gaebel W, Awad R.
34. Naber D, Riedel M, Klimke A, Vorbach EU, Lambert M, Kühn KU, Bender S, Bandelow B, Lemmer W, Moritz S, Dittmann RW. Randomized double blind comparison of olanzapine vs.. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand 2005, 111:106-15. 10.1111/j.1600-0447.2004.00486.x, 15667429.
35. de Haan L, Weisfelt M, Dingemans PM, Linszen DH, Wouters L. Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale. Psychopharmacol (Berl) 2002, 162:24-28.